Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment

This study assesses patient perspectives on the interest in, feasibility, and acceptability of an Integrative Oncology Program for patients at USC NCCC and HC3 Women's Clinic.

Study Overview

• Status: Recruiting
• Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm
• Intervention / Treatment: Other: Non-Interventional Study

Detailed Description

PRIMARY OBJECTIVE:

I. To measure patient knowledge, attitudes, and interest in IO program services, identify predictors of willingness to participate or refer, and potential barriers to implementation into existing clinical care workflows.

OUTLINE: This is an observational study.

Patients complete a survey and may participate in a focus group on study.

• Study Type: Observational
• Enrollment (Estimated): 10

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • Recruiting
      • USC / Norris Comprehensive Cancer Center
      • Principal Investigator: Xiaoyue M. Guo
      • Contact: Xiaoyue M. Guo; Phone Number: 323-409-3422; Email: Xiaoyue.guo@med.usc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with solid or hematologic cancer at USC NCCC outpatient clinics or Keck HC3 Women's Health outpatient clinic.

Description

Inclusion Criteria:

• Age ≥ 18 years
• Ability to understand and the willingness to participate in the study.
• English, Spanish, or Chinese speaking
• Patient of USC NCCC Outpatient Clinics or Keck HC3 Women's Health outpatient clinic.
• Diagnosed solid or hematologic Malignancy

Exclusion Criteria:

• Unable to provide informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational; Patients complete a survey and may participate in a focus group on study.	Other: Non-Interventional Study; Non-interventional study; Other Names: Non-Interventional Observational Study; Noninterventional (Observational) Study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient knowledge about Integrative Oncology (IO) program services	Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.	Through study completion, up to 1 year
Patient attitudes about IO program services	Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.	Through study completion, up to 1 year
Patient interest in IO program services	Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.	Through study completion, up to 1 year
Predictors of willingness to participate or refer	Outcome data will be collected through a survey per the study protocol. Adapted survey items from previously published studies (Larbi et al. 2021; Mao et al. 2014), including willingness to participate and pay will be used to asses this outcome.	Through study completion, up to 1 year
Potential barriers to implementation	Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.	Through study completion, up to 1 year

Collaborators and Investigators

• Sponsor: University of Southern California
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Xiaoyue M Guo, University of Southern California

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2025
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): January 31, 2028

Study Registration Dates

• First Submitted: December 23, 2025
• First Submitted That Met QC Criteria: December 24, 2025
• First Posted (Actual): December 29, 2025

Study Record Updates

• Last Update Posted (Actual): March 27, 2026
• Last Update Submitted That Met QC Criteria: March 24, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 0S-25-3 (Other Identifier: USC / Norris Comprehensive Cancer Center); P30CA014089 (U.S. NIH Grant/Contract); NCI-2025-09248 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); UP-25-00895

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No